50 Studies Every Urologist Should Know -

50 Studies Every Urologist Should Know

Philipp Dahm (Herausgeber)

Buch | Softcover
320 Seiten
2021
Oxford University Press Inc (Verlag)
978-0-19-065534-1 (ISBN)
49,85 inkl. MwSt
50 Studies Every Urologist Should Know presents key studies that have shaped the practice of urology. Selected using a rigorous methodology, the studies cover topics including reflux disease in paediatric urology, management of male erectile dysfunction and lower urinary tract symptoms, female urology and stone disease, the various forms of genitourinary cancer, and more. For each study, a concise summary is presented with an emphasis on the results and limitations of the study, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This book is a must-read for healthcare professionals in urology, as well as anyone who wants to learn more about the data behind clinical practice.

Philipp Dahm is currently Professor of Urology at the University of Minnesota and Director of Research and Education for Surgical Services at the Minneapolis Veterans Administration Health Care System. Dr. Dahm completed his residency training at Duke University in Durham, North Carolina where he subsequently joined the faculty and completed a Master of Health Sciences in Clinical Research. From 2006 - 2014 he was Associate and then Full Professor in the Department of Urology at the University of Florida (UF) in Gainesville, Florida, as well as in the later years, Residency Program Director.

Chapter 1: Radical prostatectomy versus observation for localized prostate cancer: The European Randomized Study of Screening for Prostate Cancer (ERSPC)
Chapter 2: The Influence of Finasteride on the Development of Prostate Cancer: Prostate Cancer Prevention Trial (PCPT)1
Chapter 3: MRI-Targeted or Standard Biopsy for Prostate Cancer Diagnosis: The PRECISION Trial
Chapter 4: Long-term survival among men with conservatively treated localized prostate cancer: Conservative management of prostate cancer-watchful waiting
Chapter 5: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
Chapter 6: Radical prostatectomy versus Observation in Early Prostate Cancer: Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4)
Chapter 7: Radical prostatectomy versus observation for localized prostate cancer: The PIVOT Trial
Chapter 8: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy: The Prostate Testing for Cancer and Treatment (ProtecT) trial
Chapter 9: Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy
Chapter 10: Quality of life and satisfaction with outcome among prostate-cancer survivors: Quality of life after primary treatment of localized prostate cancer
Chapter 11: Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial: The Southwest Oncology Group 8794 Trial
Chapter 12: Survival Following Primary Androgen Deprivation Therapy Among Men with Localized Prostate Cancer
Chapter 13: Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
Chapter 14: Intermittent versus Continuous Androgen Deprivation in Prostate Cancer: Intermittent androgen deprivation therapy (SWOG Trial 9346)
Chapter 15: Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer: The TAX 327 Trial
Chapter 16: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Chapter 17: Abiraterone and Increased Survival in Metastatic Prostate Cancer
Chapter 18: Enzalutamide in Metastatic Prostate Cancer before Chemotherapy: The PREVAIL Study
Chapter 19: The EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
Chapter 20: Nephrectomy Followed by Interferon Alfa-2b Compared With Interferon Alfa-2b Alone For Metastatic Renal-Cell Cancer
Chapter 21: Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Chapter 22: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma: CheckMate 025
Chapter 23: The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of Follow-Up
Chapter 24: Bacillus Calmette-Guerin (BCG) Immunotherapy for Recurrent Non-Invasive Transitional Cell Carcinoma of the Bladder: A Randomized Southwest Oncology Group Study
Chapter 25: Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
Chapter 26: Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
Chapter 27: A Randomized Comparison of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group Study
Chapter 28: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
Chapter 29: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-045
Chapter 30: Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer
Chapter 31: Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide: PVB versus BEP
Chapter 32: Urinary Volume, Water and Stones Recurrence in Idiopathic Calcium Nephrolithiasis: a 5-Year Randomized Prospective Study
Chapter 33: A Prospective Study of Dietary Calcium and Other Nutrients and the Risk of Symptomatic Kidney Stones
Chapter 34: First Clinical Experience with Extracorporeally Induced Destruction of Kidney Stones by Shock Waves
Chapter 35: Shockwave lithotripsy versus ureteroscopy for lower pole caliceal calculi 1 cm or less
Chapter 36: Extracorporeal shockwave lithotripsy versus percutaneous nephrolithotomy for lower pole nephrolithiasis: The Lower Pole I Study
Chapter 37: Medical Expulsive Therapy in Adults with Ureteric Colic: The SUSPEND Trial
Chapter 38: Burch Colposuspension versus Fascial Sling to Reduce Urinary Stress Incontinence: The Stress Incontinence Surgical Treatment Efficacy (SISTEr) Trial
Chapter 39: Retropubic versus Transobturator Midurethral Slings for Stress Incontinence: The Trial of Mid Urethral Slings (TOMUS)
Chapter 40: A midurethral sling to reduce incontinence after vaginal prolapse repair: The Outcomes Following Vaginal Prolapse Repair and Midurethral Sling (OPUS) trial
Chapter 41: A Randomized Trial of Urodynamic Testing Before Stress Incontinence Surgery: The VALUE Study
Chapter 42: Anticholinergic Therapy versus Onabotulinumtoxin A for Urgency Urinary Incontinence: The Anticholinergic versus Botulinum Toxin Comparison-ABC-study
Chapter 43: Oral sildenafil in the treatment of erectile dysfunction
Chapter 44: Treatment of men with erectile dysfunction with transurethral alprostadil
Chapter 45: Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux: Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial
Chapter 46: A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia: The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate
Chapter 47: The Efficacy of Terazosin, Finasteride, or both in Benign Prostatic Hyperplasia: The Veterans Affairs Cooperative Benign Prostatic Hyperplasia Study
Chapter 48: Chlorhexidine-Alcohol versus Povidone- Iodine for Surgical-Site Antisepsis
Chapter 49: Clean, Intermittent Self-Catheterization in the Treatment of Urinary Tract Disease
Chapter 50: The Surgical Learning Curve for Prostate Cancer Control after Radical Prostatectomy

Erscheinungsdatum
Reihe/Serie Fifty Studies Every Doctor Should Know
Verlagsort New York
Sprache englisch
Maße 231 x 155 mm
Gewicht 476 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Urologie
ISBN-10 0-19-065534-8 / 0190655348
ISBN-13 978-0-19-065534-1 / 9780190655341
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Intensivkurs zur Weiterbildung

von Axel Hegele; Lennart Skrobek

Buch (2022)
Thieme (Verlag)
150,00
in zwei Bänden

von Dieter Jocham; Kurt Miller; Maximilian Burger; Mark Schrader

Buch (2020)
Thieme (Verlag)
230,00